Skip to main content

Publication: secondary analysis MAC27, MAC4, MAC15 and PRC3

Publication: secondary analysis MAC4 MAC15 and PRC3
MAC27
Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets
El Kababji S, Mitsakakis N, Fang X, Beltran-Bless A-A, Pond G, Vandermeer L, Radhakrishnan D, Mosquera L, Paterson A, Shepherd L, Chen B, Barlow WE, Gralow J, Savard M-F, Clemons M, Emam KE. Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets. JCO Clinical Cancer Informatics e2300116. 2023.
 
MAC4
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers
Luen SJ, Brown LC, van Geelen CT, Savas P, Kammler R, Dell'Orto P, Biasi O, Coates AS, Gelber RD, Thürlimann B, Colleoni M, Fleming GF, Francis PA, Regan MM, Viale G, Loi S. Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials. JCO Precision Oncology, no9, e2400599. 2025.
https://ascopubs.org/doi/abs/10.1200/PO-24-00599
 
The researchers investigated whether hormone receptor–positive, human epidermal growth factor receptor 2–low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characteristics. Their findings do not support HER2-low breast cancer as a distinct clinical or biologic entity among HR+HER2- early breast cancers. Absolute differences in median ERBB2 copy number levels or gene expression are small and of unclear biologic relevance.
 
MAC15
 
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer
Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Unger JM, Tripathy D, Hortobagyi GN, Pusztai L, Kalinsky K. Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial (ONLINE). JNCI: Journal of the National Cancer Institute 2024.
https://doi.org/10.1093/jnci/djae314
 
The phase III RxPONDER trial has affected treatment for node-positive (1-3), hormone receptor-positive, HER2-negative breast cancer with a 21-gene recurrence score (RS) less than 26. Researchers investigated how these findings apply to different racial and ethnic groups within the trial.
 
Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer
Jagsi R, Barlow WE, Woodward WA, Connolly E, Mahtani R, Shumway D, Speers C, Stecklein SR, Zeidan Y, Zhang H, Sharma P, Pusztai L, Hortobagyi GN, Kalinsky K. Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. JAMA Oncology 9: 1083-1089. 2023.
https://doi.org/10.1001/jamaoncol.2023.1984
 
Observational analysis of patients enrolled in the phase III RxPONDER trial revealed a cumulative incidence of LRR between 1 and 5 years of 0.85% among patients who underwent breast-conserving surgery and radiotherapy with RNI; 0.55% after breast-conserving surgery with radiotherapy without RNI; 0.11% after mastectomy with postmastectomy radiotherapy; and 1.7% after mastectomy without radiotherapy.
 
PRC3

Molecular features of prostate cancer after neoadjuvant therapy in the phase III trial CALGB

Sumiyoshi T, Wang X, Warner EW, Sboner A, Annala M, Sigouros M, Beja K, Mizuno K, Ku S, Fazli L, Eastham J, Taplin M-E, Simko J, Halabi S, Morris MJ, Gleave ME, Wyatt AW, Beltran H. Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. JNCI: Journal of the National Cancer Institute 116: 115-126. 2024.
https://doi.org/10.1093/jnci/djad184 
 
The phase III CALGB 90203 (Alliance) trial evaluated neoadjuvant chemohormonal therapy for high-risk localized prostate cancer before radical prostatectomy. Researchers dissected the molecular features of post-treated tumors with long-term clinical outcomes to explore mechanisms of response and resistance to chemohormonal therapy.